Journal article
Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Abstract
The benefits of bisphosphonates (BPs) in reducing skeletal-related events (SREs) in patients with bone metastases has mainly been attributed to their potent osteoclast inhibiting effect. However, despite the use of modern systemic anticancer therapy including potent BPs, many patients with bone metastases continue to have SREs. An improved understanding of the fundamental mechanisms of bone destruction allows for further development of …
Authors
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Journal
Oncology Reports, Vol. 21, No. 5, pp. 1153–1159
Publisher
Spandidos Publications
Publication Date
April 6, 2009
DOI
10.3892/or_00000335
ISSN
1021-335X